Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Dec 10;37(35):3350-3358.
doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

Meredith M Regan  1   2 , Lillian Werner  1 , Sumati Rao  3 , Komal Gupte-Singh  3 , F Stephen Hodi  1   2 , John M Kirkwood  4 , Harriet M Kluger  5 , James Larkin  6 , Michael A Postow  7   8 , Corey Ritchings  3 , Mario Sznol  9 , Ahmad A Tarhini  10 , Jedd D Wolchok  7   8 , Michael B Atkins  11 , David F McDermott  2   12
Affiliations
Clinical Trial

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

Meredith M Regan et al. J Clin Oncol. .

Abstract

Purpose: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points.

Methods: We pooled data from the CheckMate 067 and 069 clinical trials of nivolumab and ipilimumab, as monotherapies or in combination, for patients with advanced melanoma. Treatment-free survival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event end points, each defined from random assignment: time to immune checkpoint inhibitor (ICI) protocol therapy cessation and time to subsequent systemic therapy initiation or death. TFS was partitioned as time with and without toxicity by a third end point, time to cessation of both ICI therapy and toxicity. Toxicity included persistent and late-onset grade 3 or higher TRAEs. The area under each Kaplan-Meier curve was estimated by the 36-month restricted mean time.

Results: At 36 months, many of the 1,077 patients who initiated ICI therapy were surviving free of subsequent therapy initiation (47% nivolumab plus ipilimumab, 37% nivolumab, 15% ipilimumab). The restricted mean TFS was longer for nivolumab plus ipilimumab (11.1 months) compared with nivolumab (4.6 months; difference, 6.5 months; 95% CI, 5.0 to 8.0 months) or ipilimumab (8.7 months; difference, 2.4 months; 95% CI, 0.8 to 4.1 months); restricted mean TFS represented 31% (3% with and 28% without toxicity), 13% (1% and 11%), and 24% (less than 1% and 23%) of the 36-month period, respectively, in the three treatment groups. TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months).

Conclusion: The analysis of TFS between ICI cessation and subsequent therapy initiation revealed longer TFS without toxicity for patients with advanced melanoma who received nivolumab plus ipilimumab compared with nivolumab or ipilimumab. Regardless of treatment, a small proportion of the TFS involved grade 3 or higher TRAEs.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Illustration of the end points that partition the area under the overall survival curve into treatment-free survival (TFS) and other resulting health states. (*) Time after cessation of immuno-oncology (IO) protocol therapy without toxicity before initiation of subsequent systemic anticancer therapy or death. (†) Time after cessation of IO protocol therapy with toxicity while treatment free. (‡) Includes toxicity that persisted since protocol therapy and toxicity that newly presented after protocol therapy cessation.
FIG 2.
FIG 2.
Swimmer plots of treatment-free interval between immuno-oncology (IO) protocol therapy cessation and subsequent systemic anticancer (SSAC) therapy initiation for individual patients with advanced melanoma in the CheckMate 067 and 069 trials. Plotted is a random sample of 100 patients per treatment group for (A) nivolumab (NIVO) plus ipilimumab (IPI), (B) NIVO, and (C) IPI. The x-axis is oriented relative to cessation of IO protocol therapy and is truncated at 24 months before and 30 months after cessation. (*) Patients who remained on IO protocol therapy had therapy duration censored at the origin. (†) Treatment-free intervals were highlighted by setting the origin of the x-axis as the point of IO protocol therapy cessation and sorting the individual patients by duration of the treatment-free interval.
FIG 3.
FIG 3.
Kaplan-Meier estimates of overall survival (OS) over the 36-month period since random assignment and restricted mean OS according to treatment group. IPI, ipilimumab; NIVO, nivolumab.
FIG 4.
FIG 4.
Estimates of treatment-free survival (TFS) and other health states over the 36-month period since random assignment according to treatment group. Data labels represent the mean number of months in any health state and the percentage of time in the 36-month period. IO, immuno-oncology; IPI, ipilimumab; NIVO, nivolumab; SSAC, subsequent systemic anticancer therapy.
FIG 5.
FIG 5.
Estimates of treatment-free survival (TFS) with and without toxicity and other health states over the 36-month period since random assignment, according to treatment group. Toxicity is defined alternatively by (A) grade 3 or higher treatment-related adverse events (TRAEs), (B) grade 2 or higher TRAEs, and (C) immunomodulatory medication use for any-grade TRAE. IO, immuno-oncology; IPI, ipilimumab; NIVO, nivolumab, SSAC, subsequent systemic anticancer therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kreamer KM. Immune checkpoint blockade: A new paradigm in treating advanced cancer. J Adv Pract Oncol. 2014;5:418–431. - PMC - PubMed
    1. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95. - PMC - PubMed
    1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116. - PubMed
    1. Callahan MK, Kluger H, Postow MA, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36:391–398. - PMC - PubMed
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. - PMC - PubMed

Publication types